Media Thread, page-10254

It also highlights the other great aspects of CF33/Vaxinia/Oncarlytics. They induce an immune response as was highlighted
In the ESMO presentation that seemed to go by unnoticed on these threads.

Plus our products have a memory. An maybe even more important is the several methods of action. We have seen from information provided with the Azer-Cel announcement, some patients stop responding to CarT and relapse.

CF33 multiplies in the cancer cells and burst it open and kill the cancer cell, as we’ve seen in animal models and been told by YF also works exactly the same in humans. Then the CD19 marks the cancers cells with receptors for the CarT therapy to attack. This is similar to the attached news article.

But we also see a Cd4 and CD8 T cell response from the bodies own immune system.

So we have 3 or 4 modes of action to obliterate the solid tumors. Then our product gives the immune system a memory to scan for cancer cells in the body should they reappear. Similar to small pox vaccines or any other vaccine for that matter.

There was not enough information in the article to know if their product searches out cancer cells hiding in the bone marrow, lymph nodes and nerve sheathing as our CF33 does.

It’s really bizarre that after all of this time as IMU rapidly progresses thru trials and is now presenting at conferences the evidence to support their verbal assertions that our products work exactly the same in humans as had been seen in animal trials, shareholders would start dumping their shares .

Once upon a time punters would buy in before expected good news. But we are now seeing them dump. Maybe they believe what they read on HC?